REGENXBIO Appoints New CSO, Dr. Gregory
Ticker: RGNX · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1590877
Sentiment: neutral
Topics: management-change, personnel
TL;DR
REGENXBIO brings in Dr. Gregory as new CSO, replacing Tang.
AI Summary
REGENXBIO Inc. announced on August 1, 2024, the appointment of Dr. Philip J. Gregory as Chief Scientific Officer, effective August 5, 2024. Dr. Gregory will receive an annual base salary of $425,000 and will be eligible for equity awards and an annual bonus. The company also reported the departure of Dr. V. Michael Tang as Chief Scientific Officer on August 1, 2024.
Why It Matters
The appointment of a new Chief Scientific Officer can signal a shift in the company's research and development strategy or a focus on specific therapeutic areas.
Risk Assessment
Risk Level: medium — Changes in key scientific leadership can impact the direction and execution of the company's research pipeline.
Key Numbers
- $425,000 — Annual Base Salary (For the new Chief Scientific Officer, Dr. Philip J. Gregory.)
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- Dr. Philip J. Gregory (person) — Newly appointed Chief Scientific Officer
- $425,000 (dollar_amount) — Annual base salary for Dr. Gregory
- August 5, 2024 (date) — Effective date of Dr. Gregory's appointment
- Dr. V. Michael Tang (person) — Departing Chief Scientific Officer
- August 1, 2024 (date) — Effective date of Dr. Tang's departure and earliest event reported
FAQ
What is the effective date of Dr. Philip J. Gregory's appointment as Chief Scientific Officer?
Dr. Philip J. Gregory's appointment is effective August 5, 2024.
What is Dr. Gregory's annual base salary?
Dr. Gregory's annual base salary is $425,000.
Who is the departing Chief Scientific Officer?
Dr. V. Michael Tang is the departing Chief Scientific Officer.
When did Dr. Tang's departure become effective?
Dr. Tang's departure was effective August 1, 2024.
What other compensation is Dr. Gregory eligible for?
Dr. Gregory is eligible for equity awards and an annual bonus.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-05 18:32:31
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
Filing Documents
- d862743d8k.htm (8-K) — 22KB
- 0001193125-24-194111.txt ( ) — 137KB
- rgnx-20240801.xsd (EX-101.SCH) — 3KB
- rgnx-20240801_lab.xml (EX-101.LAB) — 17KB
- rgnx-20240801_pre.xml (EX-101.PRE) — 11KB
- d862743d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENXBIO INC. Date: August 5, 2024 By: /s/ Patrick J. Christmas II Patrick J. Christmas II Executive Vice President, Chief Legal Officer